China’s Qiming Venture Partners Leads $37M In AI-Enabled Drug Discovery Start-Up

Login to View

Insilico Medicine, a Hong Kong-based start-up specialized in next-generation artificial intelligence (AI) technology for drug discovery, has raised US$37 million in a series B round of financing led by Chinese venture capital firm Qiming Venture Partners, according to a statement released on Tuesday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in